Hinge Health (NYSE:HNGE) Given New $145.00 Price Target at Truist Financial

Hinge Health (NYSE:HNGE) had its target price upped by research analysts at Truist Financial from $112.00 to $145.00 in a report released on Tuesday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial‘s price objective suggests a potential upside of 23.41% from the stock’s current price.

Several other equities analysts have also weighed in on HNGE. Morgan Stanley increased their target price on Hinge Health from $72.00 to $108.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Canaccord Genuity Group upped their price target on Hinge Health from $105.00 to $134.00 and gave the company a “buy” rating in a research note on Tuesday. Needham & Company LLC increased their price target on shares of Hinge Health from $115.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday. Wells Fargo & Company lifted their price objective on shares of Hinge Health from $103.00 to $132.00 and gave the stock an “overweight” rating in a research note on Tuesday. Finally, Citigroup restated an “outperform” rating on shares of Hinge Health in a report on Monday, July 27th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Hinge Health currently has a consensus rating of “Moderate Buy” and an average price target of $117.40.

Hinge Health Price Performance

Shares of Hinge Health stock traded up $2.01 on Tuesday, hitting $117.49. 1,397,655 shares of the company’s stock traded hands, compared to its average volume of 1,623,602. The firm’s 50-day moving average price is $98.66 and its two-hundred day moving average price is $67.35. The stock has a market capitalization of $9.48 billion, a PE ratio of 91.85 and a beta of 1.37. Hinge Health has a one year low of $30.08 and a one year high of $118.86.

Hinge Health (NYSE:HNGE) last posted its quarterly earnings results on Monday, November 2nd. The company reported $0.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.27 by $0.44. Hinge Health had a return on equity of 51.60% and a net margin of 15.15%. The business had revenue of $234.97 million for the quarter. During the same quarter in the prior year, the business earned ($0.02) earnings per share. The firm’s revenue for the quarter was up 52.4% on a year-over-year basis. On average, analysts forecast that Hinge Health will post 1.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hinge Health news, Chairman Gabriel Mecklenburg sold 250,000 shares of the stock in a transaction dated Friday, September 11th. The stock was sold at an average price of $88.97, for a total value of $22,242,500.00. Following the completion of the sale, the chairman directly owned 250,000 shares in the company, valued at $22,242,500. This represents a 50.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel Perez sold 150,000 shares of the firm’s stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $89.44, for a total value of $13,416,000.00. Following the sale, the chief executive officer directly owned 35,470 shares in the company, valued at approximately $3,172,436.80. This represents a 80.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,024,581 shares of company stock valued at $95,632,761 in the last three months. Insiders own 18.92% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Alps Advisors Inc. acquired a new position in Hinge Health during the 3rd quarter worth approximately $595,000. Ashton Thomas Private Wealth LLC acquired a new stake in shares of Hinge Health in the third quarter valued at approximately $458,000. CenterBook Partners LP bought a new stake in shares of Hinge Health in the third quarter worth $856,000. Calamos Advisors LLC bought a new stake in shares of Hinge Health in the third quarter worth $4,779,000. Finally, Kestra Advisory Services LLC acquired a new position in Hinge Health during the third quarter worth $242,000.

Hinge Health News Summary

Here are the key news stories impacting Hinge Health this week:

• Positive Sentiment: Q3 results exceeded expectations: Hinge Health reported earnings of $0.71 per share versus consensus estimates of $0.27 and revenue of $234.97 million, up 52.4% year over year. The company also posted a 15.15% net margin and 51.6% return on equity. Hinge Health quarterly earnings report
• Positive Sentiment: Revenue outlook was raised above consensus: Hinge Health guided fourth-quarter 2026 revenue to $249 million-$251 million, compared with the $239.2 million consensus estimate. Full-year revenue guidance of $879 million-$881 million also exceeded the $858.5 million consensus. Hinge Health revenue outlook
• Positive Sentiment: Analysts raised price targets: RBC lifted its target to $135 and maintained an “outperform” rating; Canaccord raised its target to $134 with a “buy” rating; and Stifel increased its target to $135, also retaining a “buy” rating. These targets imply roughly 16% upside from recent trading levels.
• Neutral Sentiment: Management highlighted continued expansion of its technology-enabled care platform and is targeting an integrated gastrointestinal program in summer 2027, providing a potential longer-term growth catalyst.
• Negative Sentiment: The earnings beat may have been largely anticipated, and some coverage indicated results missed the higher “whisper” expectations. With HNGE trading near its 52-week high and at a high valuation, investors may be taking profits despite the favorable fundamental update. Hinge Health earnings expectations analysis

Hinge Health Company Profile

Hinge Health is a digital healthcare company focused on musculoskeletal (MSK) conditions, including back and joint pain. The company provides virtual care programs designed to help members manage pain, improve mobility and reduce the need for more costly or invasive treatments.

Its platform combines personalized exercise therapy, behavioral support, education and access to clinical professionals. Hinge Health also uses technologies such as motion-sensing wearable devices and artificial intelligence to help guide exercises, monitor progress and tailor care plans to individual needs.

Hinge Health primarily serves employers and health plans, which offer its programs to eligible members in the United States.